ENTITY

Exact Sciences (EXAS US)

38
Analysis
Health Care • United States
Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.
more
bullish•GRAIL
•28 Jul 2024 21:29

GRAIL: Detecting Early-Stage Cancers With Galleri Test, A Significant Market Opportunity

GRAIL, a fast-growing Galleri test maker, spun off from Illumina in June. The population-scale MCED screening test identifies 50+ types of cancer...

Logo
496 Views
Share
bullish•Exact Sciences
•24 May 2024 14:00

Exact Sciences Corporation: Leveraging Health Systems and Electronic Ordering Channels To Catalyze Growth! - Major Drivers

Exact Sciences Corporation's first quarter 2024 earnings. The quarter demonstrated robust performance with first quarter revenue growing by 6% to...

Logo
377 Views
Share
bullish•Exact Sciences
•29 Feb 2024 14:00

Exact Sciences Corporation: Launch Of MRD product OncoDetect & Other New Products! - Major Drivers

Exact Sciences Corporation showcased substantial growth and improved profitability throughout 2023. With a 24% increase in core revenue amounting...

Logo
355 Views
Share
bullish•Exact Sciences
•01 Dec 2023 08:05

Exact Sciences Corporation: Cologuard Market Positioning & Long-Term Growth Strategy! - Major Drivers

Exact Sciences Corporation delivered a positive result and managed an all-around beat in the quarter. During the quarter, over 10,000 new...

Logo
196 Views
Share
bullish•Exact Sciences
•27 Aug 2023 04:00

Exact Sciences Corporation: Cancer Research Through Collaborative Partnerships & Other Drivers

Exact Sciences Corporation exceeded Wall Street's revenue and earnings expectations. Revenue increased in the second quarter. Exact Sciences...

Logo
343 Views
Share
x